Yazar "Molin, Daniel L." için listeleme
-
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
Lavie, David; Timmerman, John; Garcia-Sanz, Ramon; Kim, Won Seog; Kim, Tae Min; Avigdor, Abraham; Dierickx, Daan; Jagadeesh, Deepa; Molin, Daniel L.; Herrera, Alex F. (American Society of Hematology, 2023)Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...